The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1581
ISSUE1581
September 23, 2019
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
September 23, 2019 (Issue: 1581)
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.